2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Are the Primary Drivers Supporting the Market Growth of theParoxysmal Nocturnal Hemoglobinuria (PNH) Market?
As the incidence of blood and bone marrow-related disorders continues to surge, the paroxysmal nocturnal hemoglobinuria (PNH) market is projected to grow in response. Blood disorders can affect the operation, makeup and generation of blood and its various components. When the bone marrow manufactures insufficient red, white, or platelet cells, or produces defective or damaged blood cells, bone marrow-related disorders occur. PNH, a rare blood disorder linked to bone marrow failure diseases, is intrinsically connected to blood and bone marrow-related disorders due to its influence on blood cell production, the functioning of the immune system, and the microenvironment of the bone marrow. For example, Cancer Australia revealed in August 2022 that an estimated 5,202 new cases of leukemia will be diagnosed in Australia this year, comprising 3,198 males and 2,004 females. An individual has a 1.7% likelihood (or 1 in 58) of being diagnosed with leukemia by the age of 85. This probability is notably higher for males at 2.1% (or 1 in 47), compared to females at 1.3% (or 1 in 77). Hence, the escalating number of blood and bone marrow-related disorders is stimulating the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market. One of the main drivers of the paroxysmal nocturnal hemoglobinuria (PNH) market is the increasing need for blood transfusions. Blood transfusions, which involve the administration of blood or blood products from a donor to a recipient, can significantly alleviate the symptoms and complications of PNH sufferers. According to the World Health Organization in June 2023, high-income nations, which make up only 16% of the global populace, contributed substantially to blood donations, making up 40% of the global total of 118.5 million donations. Further, the Government of Canada reported in December 2022 that blood donations in the UK saw an uptick, with 1.7 million donations recorded throughout the country in 2021. Consequently, the growing demand for blood transfusions is fuelling the growth of the paroxysmal nocturnal hemoglobinuria (PNH) market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12936&type=smp
#What Are the Key Projections for the CAGR of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market From 2025 to 2034?
The size of the paroxysmal nocturnal hemoglobinuria (PNH) market has experienced significant growth in recent times. It is projected to expand from $4.24 billion in 2024 to $4.68 billion in 2025, indicating a compound annual growth rate (CAGR) of 10.4%. The growth witnessed during the historic period is a result of increased demand for paroxysmal nocturnal hemoglobinuria treatment, higher disposable income, government programs, and increased spending on healthcare.
The market for paroxysmal nocturnal hemoglobinuria (PNH) is predicted to experience substantial expansion in the coming years. By 2029, it’s anticipated to reach a value of $6.69 billion, growing at a compound annual growth rate (CAGR) of 9.3%. This projected growth during the forecast period is attributed to factors such as an increasing elderly population, rising demand for self-care treatments, enhanced accessibility to healthcare provisions, rising instances of comorbidities, and a growing preference for personalized medical care. Key trends for this period involve the application of digital health technologies, creation of innovative treatment methods, embracement of gene therapy, and a shift towards early intervention.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12936
What Are the Latest Innovations Influencing theParoxysmal Nocturnal Hemoglobinuria (PNH) Market?
Leading firms in the paroxysmal nocturnal hemoglobinuria (PNH) market are prioritizing the creation of innovative drugs and treatments, including injectable C5 inhibitors for PNH management, in order to maintain their market standing. The function of an injectable C5 inhibitor is to prevent the complement component C5 as a monoclonal antibody, thereby reducing inflammation and tissue damage in patients with autoimmune diseases like PNH. For example, Chugai Pharmaceutical Co., a Japanese pharmaceutical company, got precedence review endorsement from China’s National Medical Products Administration (NMPA) for PNH treatment in February 2024. This acquisition positioned China as the first nation to accept PIASKY, before other major markets, paving the way for negotiations with the National Reimbursement Drug List (NRDL) within that year itself. Given that PNH is a rare ailment, it has an estimated impact on 12,740 persons in China, indicating a substantial market opportunity.
Who Are the Major Industry Players Accelerating Growth in theParoxysmal Nocturnal Hemoglobinuria (PNH) Market?
Major companies operating in the paroxysmal nocturnal hemoglobinuria (pnh) market are Pfizer Inc., Johnson & Johnson Pvt Ltd., F. Hoffmann-La Roche AG., Novartis AG, Sanofi S.A., Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., GE Healthcare, Regeneron Pharmaceuticals Inc., CSL Behring LLC, Biogen Inc., Vertex Pharmaceuticals Incorporated, Grifols S.A., Genentech Inc., Shire PLC, Alnylam Pharmaceuticals Inc., Innovent Biologics Inc., Bioverativ Inc., CinnaGen Co, BioCryst Pharmaceuticals, Omeros Corporation, Hansa Biopharma AB, Apellis Pharmaceuticals Inc., Kira Pharmaceuticals Ltd., Akari Therapeutics PLC, RA Pharmaceuticals Inc., C5 Therapeutics Inc.
Order Your Report Now For A Swift Delivery:
Which Primary Segments of the Paroxysmal Nocturnal Hemoglobinuria (PNH) Market Are Driving Growth and Industry Transformations?
The paroxysmal nocturnal hemoglobinuria (PNH) market covered in this report is segmented –
1) By Treatment Type: Medications, Bone Marrow Transplantation, Blood Transfusion, Immunosuppressive Therapy, Other Treatment Types
2) By Diagnosis Type: Flow Cytometry, High-Resolution Mass Spectrometry, Other Diagnosis Types
3) By End Use: Hospitals, Clinics, Other End Users
Subsegments:
1) By Medications: Eculizumab, Ravulizumab, Complement Inhibitors, Supportive Care Medications
2) By Bone Marrow Transplantation: Allogeneic Stem Cell Transplantation, Autologous Stem Cell transplantation
3) By Blood Transfusion: Red blood Cell Transfusion, Platelet Transfusion, Fresh Frozen Plasma Transfusion
4) By Immunosuppressive Therapy: Corticosteroids, Azathioprine, Cyclophosphamide, Mycophenolate Mofetil
5) By Other Treatment Types: Supportive Therapies, Management Of Complications
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12936&type=smp
Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theParoxysmal Nocturnal Hemoglobinuria (PNH) Market?# Market?
North America was the largest region in the paroxysmal nocturnal hemoglobinuria (PNH) market in 2024. The regions covered in paroxysmal nocturnal hemoglobinuria (PNH) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Reports Similar to the Global Paroxysmal Nocturnal Hemoglobinuria (PNH) Market 2025, By The Business Research Company:
Acute Myeloid Leukemia Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report
Cancer Clinical Decision Tools Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/cancer-clinical-decision-tool-global-market-report
Leukemia Therapeutics Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
